In this article, Michael J. Bloch, MD, writes about studies over the past 30 years that prove lower achieved blood pressure, including modest reductions in blood pressure, translates to lower cardiovascular...
In this commentary, Michael Bloch, MD, writes about the cardiovascular risk of exposure to ambient air pollution and how clinicians can play a role in mitigating exposure to reduce blood pressure and...
Rolando L. deGoma, MD, writes about how coronary calcium scores can impact patient care, especially when it comes to preventing heart disease and CVD events.
In this Editorial, Editorial Board Member Michael J. Bloch, MD, reflects on a 1985 article from Consultant’s archives about how to properly use the laboratory to monitor drug therapy among patients with...
In this commentary, Michael Bloch, MD, writes about the cardiovascular manifestations of Fabry disease in men and women, the diagnosis of patients presenting with unexplained cardiovascular disease, and...
In this commentary, a team from Johns Hopkins Medicine writes about their experiences creating and implementing a digital health platform and explains how apps can contribute to improving patients’ health.
...
In this editorial by Consultant Board Member Dr Michael Bloch, he reflects on a 1961 Consultant article about cardiovascular disease management and how it has affected him.
In this commentary, Yehuda Handelsman, MD, deconstructs the common misconception that glucose control is the only important factor for managing diabetes and CVD.
Samantha Ellingson, PharmD, BCPS, and Timothy H. Self, PharmD—Series Editor
Samantha Ellingson, PharmD, BCPS, and Timothy H. Self, PharmD—Series Editor
When considering potential drug interactions with statin therapy, it is important to consider the hepatic pathways that could be negatively impacted with the addition of new medications.
